Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nc886 antisense oligonucleotides
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Transfection (research Use), Intracellular Delivery
01
Overview
Antisense oligonucleotides (ASOs) designed to target and suppress the expression of nc886, a noncoding RNA. nc886 (also known as vtRNA2-1 or pre-miR-886) is a regulatory noncoding RNA transcribed by RNA polymerase III that acts as an inhibitor of protein kinase R (PKR). By depleting nc886 using modified antisense oligonucleotides, these therapeutics activate PKR and trigger apoptotic cell death pathways.
- Other names
- nc886-targeting antisense oligonucleotidesnc-886-targeting antisense oligonucleotidesnc 886-targeting antisense oligonucleotidesantisense oligonucleotides against nc886
02
Targets
EIF2AK2 (Interferon-induced protein kinase R)
Beyond the preview
Go deeper on nc886 antisense oligonucleotides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nc886 antisense oligonucleotides.